{"success":true,"data":{"pressRelease":{"id":"158315","rtpr_id":"nGNXbq549m-20261001","ticker":"AIM","exchange":"NYSE American","all_tickers":["AIM"],"title":"AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data","author":"Globe Newswire","published_at":"2026-10-01T13:02:00.109Z","article_body":"OCALA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.\n(https://www.globenewswire.com/Tracker?data=nZB7rRyZsAVgcCKI7zNkYWTAjWWoVDtg8eD7NwxNmALqQswZWCB3A7KgH7vjl0gMi-qjfgCvb6VFtDEEbfzTE6AkG1ZFs6TL0FY3CuQzvPU=)\n(NYSE American: AIM) (“AIM” or the “Company”) today highlighted\nrecent media coverage focused on the Company’s development strategy for\nAmpligen® (rintatolimod) in metastatic pancreatic cancer, including the\nscientific rationale for targeting immune resistance and the continued\nadvancement of the Phase 2 DURIPANC clinical trial (“DURIPANC”).\n\nRecent coverage includes:\n* Med World News: AIM ImmunoTech’s Ampligen Program Targets One of\nPancreatic Cancer’s Hardest Barriers\n(https://medworldnews.com/aim-immunotech-ampligen-pancreatic-cancer-duripanc-trial/)\n* Pharma Tech News: Inside AIM ImmunoTech’s Ampligen Strategy for Targeting\nImmune Resistance in Pancreatic Cancer\n(https://pharmatechnews.com/inside-aim-immunotechs-ampligen-strategy/)\nPancreatic cancer remains one of the most difficult cancers to treat, in part\nbecause of an immunosuppressive tumor microenvironment that can limit the\neffectiveness of immune-based therapies. Recent features have examined\nAmpligen’s potential to help address this challenge through its\nimmune-modulating activity and the rationale for evaluating the drug in\ncombination with checkpoint inhibition.\n\nAIM successfully concluded a Netherlands-approved Named Patient Program\n(“NPP”) in which 57 patients with radiologically stable pancreatic cancer\nafter FOLFIRINOX received Ampligen as a maintenance treatment, with highly\nencouraging findings of Overall Survival, safety and improved Quality of Life.\nAmpligen is also being evaluated in combination with AstraZeneca’s Imfinzi®\n(durvalumab) in the Phase 2 DURIPANC clinical trial in metastatic pancreatic\ncancer, with interim reports of immune system changes that suggest a\ncoordinated activation of innate and adaptive responses, and all while the\ncombination therapy is reported as being well-tolerated and patients\nconsistently report a high Quality of Life throughout treatment. The study has\ncompleted final Ampligen dosing, representing an important clinical milestone\nas the program advances toward topline results expected in the first quarter\nof 2027.\n\n“The recent media attention around Ampligen reflects the important\nscientific rationale behind our pancreatic cancer strategy, supported by the\nmeaningful clinical progress we have made with DURIPANC,” said AIM Chief\nExecutive Officer Thomas K. Equels. “With DURIPANC final Ampligen dosing\ncomplete and topline results expected in the first quarter of 2027, we are\napproaching an important inflection point for the program. We believe that the\nNPP data combined with the upcoming DURIPANC data – including exploratory\nbiomarker analyses that may help AIM to better understand patient response –\nwill provide important insight into Ampligen’s potential role in metastatic\npancreatic cancer and help inform the design of a planned pivotal clinical\ntrial.”\n\nAbout AIM ImmunoTech Inc.\n\nAIM ImmunoTech Inc. is an immuno-pharma company focused on the research and\ndevelopment of its lead product, Ampligen® (rintatolimod), for the treatment\nof late-stage pancreatic cancer, a lethal and unmet global health problem.\nAmpligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that\nhas shown broad-spectrum activity in clinical trials.\n\nFor more information, please visit aimimmuno.com\n(https://www.globenewswire.com/Tracker?data=rt5J3rgF5MK9CALzA83DjRZ43zxT22FanIcEXr78l1FCFK_S-WXVHv3JrGk8TR3WT0R_HTfP3HdDRKgh2opAhwyKhlUeOC7bqMOvntGm4r-f7-PUkmkF0YgmCwMWbxWEGEWWF2LBEejlEalbv9s983MshNMTGbOmPpOXqS4PsOp3bhosMo82VLQ1d4sGgRNwCSfJAUsaRFPeoUD96DcksHFTvVtvKDSvPe8hKwLsK2A=) and\nconnect with the Company on X\n(https://www.globenewswire.com/Tracker?data=Er59cBP3egh1DypNalBpzBgYIyKVy8OgPhk-j0ulHe6aYKgfnxWdE5kxcRj_OJV1YAqcUwuqjh3-IpkjwaC8O_a3XyWCUFPuSUIsPDbv56Dh9lPDFLR6GWk06iIzR0EbXEaakTsshS4VlAcMcv34cG7UOd5Gy9MYVfSSHKhN-zGLkE5m08BRPHd5D6lI7oGURviOKImEe5xYE-m-D8-IEQ==), LinkedIn\n(https://www.globenewswire.com/Tracker?data=5sZue4wBtp1Notvf87pm_68HqsMFzmlU48tqIq3lOuNNXorD4LqvDSaYpomMEGY8e-AaVFX6RXBOsgeAa-FGBVNyi4IADNbzueVPKad1ESIpYuvGV7XwfDYSfvEdThIjAT4XcE9bSOIBQD6n_bBFEuLGSh1JZWIALyNMpX_QIkT5CPQBECH3gInsnmgPnwPbWtrOhIHJrSuE55mxp37NylS94_gOdpNgyM0dlujdP-OXgkpeI7ve_aErnNnYn9FU),\nand Facebook\n(https://www.globenewswire.com/Tracker?data=5E35SzlfFxQI5CrKAjwlgandrY9QCVjXJ-jad94XUxzV5rEkxZi4cHgL_DzUmV_p548Yt16mpbZub3iqw8bM6gbnszoYv-19-2PkU5x7NH1pv_sAqpkVXpFUcIIO4ACgadWhTIfTDRKRVgRylyEoxV5JfYZZ0IbDaWBFB_tSeJNjYudg75c3Li3GDwFSb5Ji_88RYU9gRRv2VkQmPGYJkuCuCCF43QkUVrU5x0IUibOYOQgfD-ZAAB2rHTd6PCS8).\n\nCautionary Statement\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, that involve a number of risks\nand uncertainties. Any forward-looking statements set forth in this press\nrelease speak only as of the date hereof. Such forward-looking statements may\ninclude statements relating, but not limited to: the potential of Ampligen to\naddress immune resistance in pancreatic cancer through its immune-modulating\nactivity; the potential of Ampligen in combination with AstraZeneca’s\nImfinzi (durvalumab) in the Phase 2 DURIPANC clinical trial; and the timing\nand outcome of the DURIPANC topline results; the Company’s long-term\npancreatic cancer development strategy and its efforts to position Ampligen\nfor the next stage of development; and the Company’s ability to create\nlong-term value for its stockholders. Forward-looking statements include\nstatements attributed to, or made by, the Company’s Chief Executive Officer\nin this press release. For all forward-looking statements, the Company claims\nthe protection of the safe harbor for forward-looking statements contained in\nthe Private Securities Litigation Reform Act of 1995. All statements in this\npress release other than statements of historical fact, including statements\nregarding the potential of Ampligen’s mechanism of action, anticipated\nregulatory milestones, our future results of operations and financial\nposition, our business strategy and plans, and our objectives for future\noperations, are forward-looking statements. Words such as “believe,”\n“may,” “might,” “will,” “could,” “should,” “can,”\n“estimate,” “continue,” “anticipate,” “intend,” “expect,”\n“envision,” “potential” and similar expressions are intended to\nidentify forward-looking statements, but the absence of these words does not\nmean that a statement is not forward-looking. The Company does not undertake\nto update any of these forward-looking statements to reflect events or\ncircumstances that occur after the date hereof, except as required by\napplicable law. The Company is in various stages of seeking to determine\nwhether Ampligen will be effective in the treatment of multiple types of viral\ndiseases, cancers, and immune-deficiency disorders, and disclosures in the\nCompany’s reports filed with the SEC, on its website, and in its press\nreleases set forth its current and anticipated future activities. These\nactivities are subject to change for a number of reasons. Significant\nadditional testing and trials will be required to determine whether Ampligen®\nwill be effective in the treatment of these conditions. Results obtained in\npreclinical studies do not necessarily predict results in humans. Human\nclinical trials will be necessary to prove whether or not Ampligen® will be\nefficacious in humans. No assurance can be given as to whether current or\nplanned clinical trials will be successful or yield favorable data, and the\ntrials are subject to many factors including lack of regulatory approval(s),\nlack of study drug, lack of adequate funding, or a change in priorities at the\ninstitutions sponsoring other trials. Even if these clinical trials are\ninitiated, the Company cannot assure that the clinical studies will be\nsuccessful or yield any useful data. No assurance can be given that the\nfindings in preliminary studies will prove true or that such studies will\nyield favorable results, or that future studies will not result in findings\nthat are different from those reported in the studies referenced in the\nCompany’s reports filed with the SEC, on the Company’s website, and in its\npress releases. Operating in foreign countries carries with it a number of\nrisks, including potential difficulties in enforcing intellectual property\nrights. The Company cannot assure that its potential foreign operations will\nnot be adversely affected by these risks.\n\nFor a detailed discussion of these and other risk factors, please review the\n“Risk Factors” section in the Company’s most recent Annual Report on\nForm 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S.\nSecurities and Exchange Commission. These filings are available at www.sec.gov\nand www.aimimmuno.com. You should not place undue reliance on any\nforward-looking statements. The information found on the Company’s website\nor on other websites referenced or linked to in this press release is not\nincorporated by reference into this press release and such information is\nreferenced or linked for reference purposes only.\n\nInvestor Contact:\n\nJTC Team, LLC\nJenene Thomas\n908.824.0775\nAIM@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8e85b83b-047f-4f99-9c51-1aa232ffe9bb)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbq549m-20261001","title":"AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data","author":"Globe Newswire","ticker":"AIM","created":"2026-10-01T13:02:00.109Z","tickers":["AIM"],"exchange":"NYSE American","article_body":"OCALA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.\n(https://www.globenewswire.com/Tracker?data=nZB7rRyZsAVgcCKI7zNkYWTAjWWoVDtg8eD7NwxNmALqQswZWCB3A7KgH7vjl0gMi-qjfgCvb6VFtDEEbfzTE6AkG1ZFs6TL0FY3CuQzvPU=)\n(NYSE American: AIM) (“AIM” or the “Company”) today highlighted\nrecent media coverage focused on the Company’s development strategy for\nAmpligen® (rintatolimod) in metastatic pancreatic cancer, including the\nscientific rationale for targeting immune resistance and the continued\nadvancement of the Phase 2 DURIPANC clinical trial (“DURIPANC”).\n\nRecent coverage includes:\n* Med World News: AIM ImmunoTech’s Ampligen Program Targets One of\nPancreatic Cancer’s Hardest Barriers\n(https://medworldnews.com/aim-immunotech-ampligen-pancreatic-cancer-duripanc-trial/)\n* Pharma Tech News: Inside AIM ImmunoTech’s Ampligen Strategy for Targeting\nImmune Resistance in Pancreatic Cancer\n(https://pharmatechnews.com/inside-aim-immunotechs-ampligen-strategy/)\nPancreatic cancer remains one of the most difficult cancers to treat, in part\nbecause of an immunosuppressive tumor microenvironment that can limit the\neffectiveness of immune-based therapies. Recent features have examined\nAmpligen’s potential to help address this challenge through its\nimmune-modulating activity and the rationale for evaluating the drug in\ncombination with checkpoint inhibition.\n\nAIM successfully concluded a Netherlands-approved Named Patient Program\n(“NPP”) in which 57 patients with radiologically stable pancreatic cancer\nafter FOLFIRINOX received Ampligen as a maintenance treatment, with highly\nencouraging findings of Overall Survival, safety and improved Quality of Life.\nAmpligen is also being evaluated in combination with AstraZeneca’s Imfinzi®\n(durvalumab) in the Phase 2 DURIPANC clinical trial in metastatic pancreatic\ncancer, with interim reports of immune system changes that suggest a\ncoordinated activation of innate and adaptive responses, and all while the\ncombination therapy is reported as being well-tolerated and patients\nconsistently report a high Quality of Life throughout treatment. The study has\ncompleted final Ampligen dosing, representing an important clinical milestone\nas the program advances toward topline results expected in the first quarter\nof 2027.\n\n“The recent media attention around Ampligen reflects the important\nscientific rationale behind our pancreatic cancer strategy, supported by the\nmeaningful clinical progress we have made with DURIPANC,” said AIM Chief\nExecutive Officer Thomas K. Equels. “With DURIPANC final Ampligen dosing\ncomplete and topline results expected in the first quarter of 2027, we are\napproaching an important inflection point for the program. We believe that the\nNPP data combined with the upcoming DURIPANC data – including exploratory\nbiomarker analyses that may help AIM to better understand patient response –\nwill provide important insight into Ampligen’s potential role in metastatic\npancreatic cancer and help inform the design of a planned pivotal clinical\ntrial.”\n\nAbout AIM ImmunoTech Inc.\n\nAIM ImmunoTech Inc. is an immuno-pharma company focused on the research and\ndevelopment of its lead product, Ampligen® (rintatolimod), for the treatment\nof late-stage pancreatic cancer, a lethal and unmet global health problem.\nAmpligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that\nhas shown broad-spectrum activity in clinical trials.\n\nFor more information, please visit aimimmuno.com\n(https://www.globenewswire.com/Tracker?data=rt5J3rgF5MK9CALzA83DjRZ43zxT22FanIcEXr78l1FCFK_S-WXVHv3JrGk8TR3WT0R_HTfP3HdDRKgh2opAhwyKhlUeOC7bqMOvntGm4r-f7-PUkmkF0YgmCwMWbxWEGEWWF2LBEejlEalbv9s983MshNMTGbOmPpOXqS4PsOp3bhosMo82VLQ1d4sGgRNwCSfJAUsaRFPeoUD96DcksHFTvVtvKDSvPe8hKwLsK2A=) and\nconnect with the Company on X\n(https://www.globenewswire.com/Tracker?data=Er59cBP3egh1DypNalBpzBgYIyKVy8OgPhk-j0ulHe6aYKgfnxWdE5kxcRj_OJV1YAqcUwuqjh3-IpkjwaC8O_a3XyWCUFPuSUIsPDbv56Dh9lPDFLR6GWk06iIzR0EbXEaakTsshS4VlAcMcv34cG7UOd5Gy9MYVfSSHKhN-zGLkE5m08BRPHd5D6lI7oGURviOKImEe5xYE-m-D8-IEQ==), LinkedIn\n(https://www.globenewswire.com/Tracker?data=5sZue4wBtp1Notvf87pm_68HqsMFzmlU48tqIq3lOuNNXorD4LqvDSaYpomMEGY8e-AaVFX6RXBOsgeAa-FGBVNyi4IADNbzueVPKad1ESIpYuvGV7XwfDYSfvEdThIjAT4XcE9bSOIBQD6n_bBFEuLGSh1JZWIALyNMpX_QIkT5CPQBECH3gInsnmgPnwPbWtrOhIHJrSuE55mxp37NylS94_gOdpNgyM0dlujdP-OXgkpeI7ve_aErnNnYn9FU),\nand Facebook\n(https://www.globenewswire.com/Tracker?data=5E35SzlfFxQI5CrKAjwlgandrY9QCVjXJ-jad94XUxzV5rEkxZi4cHgL_DzUmV_p548Yt16mpbZub3iqw8bM6gbnszoYv-19-2PkU5x7NH1pv_sAqpkVXpFUcIIO4ACgadWhTIfTDRKRVgRylyEoxV5JfYZZ0IbDaWBFB_tSeJNjYudg75c3Li3GDwFSb5Ji_88RYU9gRRv2VkQmPGYJkuCuCCF43QkUVrU5x0IUibOYOQgfD-ZAAB2rHTd6PCS8).\n\nCautionary Statement\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, that involve a number of risks\nand uncertainties. Any forward-looking statements set forth in this press\nrelease speak only as of the date hereof. Such forward-looking statements may\ninclude statements relating, but not limited to: the potential of Ampligen to\naddress immune resistance in pancreatic cancer through its immune-modulating\nactivity; the potential of Ampligen in combination with AstraZeneca’s\nImfinzi (durvalumab) in the Phase 2 DURIPANC clinical trial; and the timing\nand outcome of the DURIPANC topline results; the Company’s long-term\npancreatic cancer development strategy and its efforts to position Ampligen\nfor the next stage of development; and the Company’s ability to create\nlong-term value for its stockholders. Forward-looking statements include\nstatements attributed to, or made by, the Company’s Chief Executive Officer\nin this press release. For all forward-looking statements, the Company claims\nthe protection of the safe harbor for forward-looking statements contained in\nthe Private Securities Litigation Reform Act of 1995. All statements in this\npress release other than statements of historical fact, including statements\nregarding the potential of Ampligen’s mechanism of action, anticipated\nregulatory milestones, our future results of operations and financial\nposition, our business strategy and plans, and our objectives for future\noperations, are forward-looking statements. Words such as “believe,”\n“may,” “might,” “will,” “could,” “should,” “can,”\n“estimate,” “continue,” “anticipate,” “intend,” “expect,”\n“envision,” “potential” and similar expressions are intended to\nidentify forward-looking statements, but the absence of these words does not\nmean that a statement is not forward-looking. The Company does not undertake\nto update any of these forward-looking statements to reflect events or\ncircumstances that occur after the date hereof, except as required by\napplicable law. The Company is in various stages of seeking to determine\nwhether Ampligen will be effective in the treatment of multiple types of viral\ndiseases, cancers, and immune-deficiency disorders, and disclosures in the\nCompany’s reports filed with the SEC, on its website, and in its press\nreleases set forth its current and anticipated future activities. These\nactivities are subject to change for a number of reasons. Significant\nadditional testing and trials will be required to determine whether Ampligen®\nwill be effective in the treatment of these conditions. Results obtained in\npreclinical studies do not necessarily predict results in humans. Human\nclinical trials will be necessary to prove whether or not Ampligen® will be\nefficacious in humans. No assurance can be given as to whether current or\nplanned clinical trials will be successful or yield favorable data, and the\ntrials are subject to many factors including lack of regulatory approval(s),\nlack of study drug, lack of adequate funding, or a change in priorities at the\ninstitutions sponsoring other trials. Even if these clinical trials are\ninitiated, the Company cannot assure that the clinical studies will be\nsuccessful or yield any useful data. No assurance can be given that the\nfindings in preliminary studies will prove true or that such studies will\nyield favorable results, or that future studies will not result in findings\nthat are different from those reported in the studies referenced in the\nCompany’s reports filed with the SEC, on the Company’s website, and in its\npress releases. Operating in foreign countries carries with it a number of\nrisks, including potential difficulties in enforcing intellectual property\nrights. The Company cannot assure that its potential foreign operations will\nnot be adversely affected by these risks.\n\nFor a detailed discussion of these and other risk factors, please review the\n“Risk Factors” section in the Company’s most recent Annual Report on\nForm 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S.\nSecurities and Exchange Commission. These filings are available at www.sec.gov\nand www.aimimmuno.com. You should not place undue reliance on any\nforward-looking statements. The information found on the Company’s website\nor on other websites referenced or linked to in this press release is not\nincorporated by reference into this press release and such information is\nreferenced or linked for reference purposes only.\n\nInvestor Contact:\n\nJTC Team, LLC\nJenene Thomas\n908.824.0775\nAIM@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8e85b83b-047f-4f99-9c51-1aa232ffe9bb)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-01T13:02:00.218081866Z","server_sent_at_ms":1790859720218},"received_at":"2026-10-01T13:02:00.366Z","source_url":null},"analysis":{"id":"146951","press_release_id":"158315","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["release recycles prior milestones and media coverage rather than new clinical data","topline data is a future binary event with no assured success; forward-looking risk factors apply"],"eventType":"clinical_trial","narrative":"AIM ImmunoTech issued a release spotlighting recent media coverage of its Ampligen strategy in metastatic pancreatic cancer, with final Ampligen dosing complete in the Phase 2 DURIPANC trial.\n\nTopline DURIPANC results, testing Ampligen plus AstraZeneca's Imfinzi, are expected in the first quarter of 2027 and management calls the readout an important inflection point for the program.\n\nThe release also cites a Netherlands-approved Named Patient Program in 57 patients that showed encouraging overall survival, safety, and quality-of-life findings, and says NPP data plus DURIPANC biomarker analyses will inform a planned pivotal trial.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Promotional coverage-citation PR ahead of a Q1 2027 DURIPANC topline catalyst -- watch, don't act."},"keyFigures":{"drugName":"Ampligen (rintatolimod)","phaseOfTrial":"Phase 2","customDimensions":{"npp_patients":57,"topline_data_timing":"first quarter of 2027"}},"quotedText":"With DURIPANC final Ampligen dosing complete and topline results expected in the first quarter of 2027, we are approaching an important inflection point for the program.","namedEntities":{"people":[{"name":"Thomas K. Equels","role":"CEO"},{"name":"Jenene Thomas","role":"investor relations contact, JTC Team"}],"products":["Ampligen","rintatolimod","Imfinzi","durvalumab","FOLFIRINOX"],"companies":[{"name":"AIM ImmunoTech Inc.","ticker":"AIM","relationship":"filer"},{"name":"AstraZeneca","relationship":"partner (Imfinzi supplied for DURIPANC combination)"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Issuer PR highlighting media coverage and reiterating that DURIPANC final dosing is complete with topline data expected Q1 2027. No new clinical results; the actual binary catalyst remains months away."},"tickerRelevance":{"others":[],"primary":"AIM"},"globalImportance":20,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"promotional-milestone-recap","catalystTiming":"Q1 2027 topline","issuerAuthored":true}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"AIM ImmunoTech issued a release spotlighting recent media coverage of its Ampligen strategy in metastatic pancreatic cancer, with final Ampligen dosing complete in the Phase 2 DURIPANC trial.\n\nTopline DURIPANC results, testing Ampligen plus AstraZeneca's Imfinzi, are expected in the first quarter of 2027 and management calls the readout an important inflection point for the program.\n\nThe release also cites a Netherlands-approved Named Patient Program in 57 patients that showed encouraging overall survival, safety, and quality-of-life findings, and says NPP data plus DURIPANC biomarker analyses will inform a planned pivotal trial.","key_figures":{"drugName":"Ampligen (rintatolimod)","phaseOfTrial":"Phase 2","customDimensions":{"npp_patients":57,"topline_data_timing":"first quarter of 2027"}},"named_entities":{"people":[{"name":"Thomas K. Equels","role":"CEO"},{"name":"Jenene Thomas","role":"investor relations contact, JTC Team"}],"products":["Ampligen","rintatolimod","Imfinzi","durvalumab","FOLFIRINOX"],"companies":[{"name":"AIM ImmunoTech Inc.","ticker":"AIM","relationship":"filer"},{"name":"AstraZeneca","relationship":"partner (Imfinzi supplied for DURIPANC combination)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T13:02:08.831Z","global_importance":20,"audience_relevance":18,"importance_components":{"tickerTier":"micro-cap","eventGravity":"promotional-milestone-recap","catalystTiming":"Q1 2027 topline","issuerAuthored":true}},"durationMs":8456,"modelName":"glm-5.3-flashx"}}